Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Mr

FY 2023-24

Summary
Plaque buildup from atherosclerosis is the underlying root of coronary artery disease (CAD) which is the leading cause of death in the world. Moderate-severe CAD is treated with percutaneous coronary intervention, a balloon catheter is introduced into the vascular system and inflated at the plaque site to widen the lumen and restore blood flow. However, endothelial cells (ECs) and smooth muscle cells (SMCs) in the arterial wall can get damaged in the intervention. This triggers SMC migration into the intimal layer leading to intimal thickening and eventually restenosis or re-narrowing. Re-establishment of the EC layer is essential to preventing blood clots. Drug-coated balloons or stents (Sirolimus or Paclitaxel) are being used to prevent restenosis. However, they are indiscriminately cytotoxic and kill ECs which risks late thrombosis, necessitating prolonged anti-platelet therapy. A cell-specific strategy to inhibit SMC-driven intimal thickening without harming ECs is needed to prevent restenosis. Our lab previously identified loss of N-cadherin cell adhesions between SMCs and ECs as a trigger for unregulated SMC migration. Based on this, we generated an N-cadherin mimetic peptide that engages with N-cadherin on SMCs to simulate an intact endothelium and prevent migration. We recently showed peptide infusions in an injured rat carotid artery reduced intimal thickening for 2 weeks. We are now working on testing and developing a novel in vivo delivery method by coating the peptide on nanoparticles and loading them onto balloons. They can be delivered to arteries in vivo during an angioplasty as a preventative therapy for restenosis. The rise in nanomedicine and cell-specific therapies has created safer treatments, our peptide coated nanoparticles is a product of both.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
505850
Name
Appings Ryan C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mr
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atherosclerosis; Balloon Angioplasty; Carotid Artery; Cell Specific Treatment; N-Cadherin; Nanomedicine; Peptide Coated Nanoparticles; Restenosis; Smooth Muscle Cells; Translational Medicine
Abstract
Plaque buildup from atherosclerosis is the underlying root of coronary artery disease (CAD) which is the leading cause of death in the world. Moderate-severe CAD is treated with percutaneous coronary intervention, a balloon catheter is introduced into the vascular system and inflated at the plaque site to widen the lumen and restore blood flow. However, endothelial cells (ECs) and smooth muscle cells (SMCs) in the arterial wall can get damaged in the intervention. This triggers SMC migration into the intimal layer leading to intimal thickening and eventually restenosis or re-narrowing. Re-establishment of the EC layer is essential to preventing blood clots. Drug-coated balloons or stents (Sirolimus or Paclitaxel) are being used to prevent restenosis. However, they are indiscriminately cytotoxic and kill ECs which risks late thrombosis, necessitating prolonged anti-platelet therapy. A cell-specific strategy to inhibit SMC-driven intimal thickening without harming ECs is needed to prevent restenosis. Our lab previously identified loss of N-cadherin cell adhesions between SMCs and ECs as a trigger for unregulated SMC migration. Based on this, we generated an N-cadherin mimetic peptide that engages with N-cadherin on SMCs to simulate an intact endothelium and prevent migration. We recently showed peptide infusions in an injured rat carotid artery reduced intimal thickening for 2 weeks. We are now working on testing and developing a novel in vivo delivery method by coating the peptide on nanoparticles and loading them onto balloons. They can be delivered to arteries in vivo during an angioplasty as a preventative therapy for restenosis. The rise in nanomedicine and cell-specific therapies has created safer treatments, our peptide coated nanoparticles is a product of both.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Appings, Ryan C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~